PCV72 Economic Evaluation of Ivabradine in Chronic Heart Failure in Greece  by Kourlaba, G. et al.
A524  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
of ivabradine plus standard therapy being cost-effective at a threshold of € 36,000/
QALY was found to be 96% in both within trial and lifetime analysis. This result is 
driven by a reduction in mortality and hospitalisations and the associated costs of 
care. ConClusions: Ivabradine added to standard care could be a cost-effective 
treatment for the treatment in CHF patients in Greece.
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With 7 million deaths per year, ischaemic heart disease is the leading cause 
of mortality worldwide. In Acute Coronary Syndrome (ACS), the vast majority 
of fatal cardiovascular events occur after hospital discharge. Guidelines recom-
mend antithrombotic treatment for secondary prevention after ACS. objeCtives: 
To assess the cost-effectiveness of rivaroxaban 2.5mg BID in combination with 
standard antiplatelet therapy (ASA alone or in combination with a thienopyri-
dine [clopidogrel or ticlopidine]) versus standard antiplatelet therapy alone for 
prevention of secondary events in ACS patients from a Swedish societal perspec-
tive. Methods: A Markov model is used to capture single and multiple events, 
costs and utilities based on the time since index event to reflect clinical practice. 
For the first 2 years the model uses data from the ATLAS ACS 2-TIMI 51 clinical 
trial including efficacy, safety, treatment discontinuation and average patient 
age. After 2 years, transition probabilities were extrapolated using an exponen-
tial function method. Estimates for life expectancy, drug acquisition costs and 
other medical and indirect costs were derived from published Swedish sources. 
Cost and effects are discounted at 3.0%. Univariate and probabilistic sensitivity 
analyses were conducted with an assumed willingness to pay (WTP) threshold of 
SEK 500,000. Results: For the base case scenario, incremental life time costs are 
estimated at SEK 10,000.44 (€ 1,156), incremental QALYs at 0.14, and incremental 
cost per QALY at SEK 71,245.76 (€ 8,236). Univariate sensitivity analyses indicate 
that the results are sensitive to changes in the cost of rivaroxaban and baseline 
utility value. At an assumed WTP of SEK 500,000, rivaroxaban in combination with 
standard antiplatelet therapy is expected to be cost-effective. ConClusions: 
From a Swedish societal perspective, secondary prevention with rivaroxaban 
2.5mg BID in combination with standard antiplatelet therapy can be considered 
a cost-effective option for patients with ACS. Sensitivity analyses demonstrated 
that the results are robust.
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objeCtives: The most common cardiac arrhythmia (atrial fibrillation, AF) 
increases the risk of morbidity and mortality. We estimated the health and eco-
nomic consequences of the use of apixaban compared with warfarin reducing the 
risk of stroke in patients with AF, from the perspective of the Instituto Mexicano 
del Seguro Social (IMSS). Methods: We performed a cost-effectiveness analysis 
using a Markov model (17 health states, six-week cycles), which simulates patients 
treated with warfarin (fixed dose: 5mg/day) or apixaban (10mg/day). Patients enter 
the model at age 70 and remain there until death (disease-related or according to 
Mexican life tables). Safety, efficacy and utilities were extracted from published 
sources. The costs of warfarin and AF-related clinical events were extracted from 
IMSS sources. The cost of apixaban was provided by the manufacturer. Costs are 
expressed in US$, 2013 and a 5% per-year discount rate was applied. Years of 
life and quality adjusted life years (QALYs) gained were the health outcomes. 
Univariate and probabilistic sensitivity analyzes were performed. Results: The 
model estimated 7.645 life years and 5.454 QALYs in the apixaban arm, which 
means 0.147 and 0.160 gained life years and QALY’s, respectively (regarding war-
farin). The costs of apixaban and warfarin were US$14,943 and US$15,042, respec-
tively (apixaban is a dominant alternative). Health gains with apixaban are driven 
by fewer event-related deaths (10/1000 patients at risk) as well as fewer hemor-
rhagic strokes (12) and bleeding (13 major bleeds, 41 clinically non-major bleeds) 
compared to warfarin-treated patients. Treatment costs are driven by drug acqui-
sition cost (apixaban) and monitoring cost (warfarin). ConClusions: Apixaban 
is more effective and safer than warfarin reducing the risk of stroke associated 
with AF, as well as bleeding events. To achieve this improvement, no additional 
economic resources need to be invested, which makes apixaban a cost-saving 
intervention in the context of the IMSS.
PCV75
Cost-EffECtiVEnEss of APixAbAn VERsus stAndARd of CARE foR 
thE PREVEntion of stRokE: An AnAlysis of PAtiEnts with AtRiAl 
fibRillAtion in GREECE
Athanasakis K.1, Arzoumanidou D.1, Karampli E.1, Armelidou E.2, Giovas P.2, Petrikkou E.3, 
Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2Pfizer Hellas, Athens, Greece, 3BMS Hellas, 
Athens, Greece
objeCtives: Apixaban is an oral anticoagulant that has demonstrated a supe-
rior clinical profile compared to warfarin and aspirin in the management of 
patients with non-valvular Atrial Fibrilation (NVAF) and at least one additional 
risk factor for stroke. The objective of the present analysis was to assess the 
cost-effectiveness of apixaban against warfarin and aspirin for the preven-
tion of stroke in patients with NVAF in Greece. Methods: A Markov model 
that evaluated clinical events, quality adjusted life expectancy and costs for 
patients treated with apixaban and warfarin or aspirin (VKA-suitable and 
Henriksson reported that surgery plus medical management can be considered 
cost effective as a treatment of asymptomatic carotid stenosis in 65 year-old men. 
He assumed a surgery relative risk reduction of 65.5%, or approximately an abso-
lute risk reduction (ARR) of 8% in this population. However, data for the compara-
tor arm (medical management alone) were dated and did not reflect efficacies 
of current medical therapies. objeCtives: To analyze using Bayesian methods, 
asymptomatic carotid stenosis clinical trial data, and more current medical therapy 
data the probability of achieving this 8% ARR and an incremental cost per QALY 
of approximately $50,000 (US, inflated - 2013 dollars). Methods: The outcome of 
interest from the clinical trials was the mean difference in the probability of any 
stroke or perioperative death between surgery (carotid endarterectomy [CEA]) and 
aggressive medical management (MM). The CEA data came from the Asymptomatic 
Carotid Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery Trial 
(ACST). The updated medical management data came from a systematic review 
published in the journal Stroke (Abbott, 2009). The Bayesian analysis employed a 
Beta-Binomial Model. Results: The posterior distribution of the Bayesian analysis 
representing the ARR of CEA versus MM had a mean of 0.008 with an essentially 
zero probability of achieving the Henriksson assumption of 8% ARR. Using the mean 
of this posterior distribution, the resulting incremental cost per QALY exceeded 
$500,000 in 65 year-old men – a value unlikely to be considered cost effective in any 
country. ConClusions: Bayesian analysis allows the prediction of the probability 
that a treatment alternative exceeds a predefined threshold. A powerful feature of 
Bayesian analysis is the ability to incorporate additional and/or newer data. This 
newer data can drastically alter assumptions about the cost effectiveness of treat-
ment alternatives.
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objeCtives: Aortic stenosis is the most common valvular heart disease in the 
elderly –its prevalence is estimated to be up to 5% in individuals over 75 years. 
Surgical replacement of aortic valve is considered the standard care and in the 
absence of serious coexisting conditions, the procedure is associated with low 
operative mortality. However, a significant proportion of patients cannot undergo 
surgery due to high surgical risk associated with advanced age or presence of 
multiple coexisting conditions. Treatment with transcatheter aortic-valve implan-
tation (TAVI) is a therapy with potentially lower peri-procedure risk and has been 
used as a therapeutic option in this group considered inoperable. This study aims 
to develop a cost-effectiveness analysis of TAVI in patients with severe aortic 
stenosis who are not suitable for surgical treatment according to Brazilian Private 
System Perspective. Methods: A Markov model was developed to compare TAVI 
versus standard therapy (drug treatment with or without aortic balloon valvulo-
plasty) with a 5-year time horizon. Outcomes in the model were based on safety 
and effectiveness (as measured by clinical outcomes of chance of successful 
implantation procedure and survival from PARTNER cohort B trial). Resource use 
included early perioperative complications (30 days) and late events. Cost data 
were obtained from Brazilian public lists (CMED/SIMPRO/CBHPM). Results were 
expressed as incremental cost-effectiveness ratio (ICER) per life years gained 
(LYG). Probabilistic sensitivity analysis was performed to confirm robustness of 
results. Results: Compared with standard therapy with or without aortic balloon 
valvuloplasty, use of TAVI improves survival in 0.97 life years with an incremental 
cost of US$43,602, resulting an ICER of US$45,080/LYG. In an alternative scenario 
considering 10-year time horizon, ICER was 27,565/LYG. ConClusions: Use of 
TAVI results in improved survival with a low risk of serious adverse events, and 
demonstrates a cost-effectiveness profile when compared to other technologies 
already incorporated in Brazil.
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objeCtives: In the SHIFT trial, ivabradine administered to chronic heart failure 
(CHF) patients in combination with standard therapy significantly reduced cardio-
vascular death and hospital admission for cardiovascular problems. An economic 
evaluation of ivabradine plus standard care against standard care alone, for the 
management CHF in patients with a baseline heart rate ≥ 75b.p.m. was conducted 
from the Greek third party-payer perspective. Methods: An existing Markov model 
consisting of two health states for CHF NYHA classes I to IV (i.e. alive, dead) was 
adapted to the Greek health care setting. In each one month cycle, patients can 
either remain alive or die, during their life span or 29 months (i.e. within SHIFT 
trial period). Health state utilities were estimated from EQ-5D index scores obtained 
from the SHIFT clinical trial and using appropriate modeling techniques the data 
were extrapolated beyond the trial period. All costing data reflects the year 2013. 
Probabilistic sensitivity analyses (PSA) were conducted. Both cost and outcomes 
were discounted at 3.5% per year. Results: Results for within trial analysis 
revealed that ivabradine had an incremental cost and incremental QALY of € 905 
and 0.05 respectively, leading to an incremental cost per QALY gained of € 16,635/
QALY. Ivabradine was a cost-effective alternative at a willingness to pay thresh-
old of € 36,000 per QALY gained Moreover, the cumulated lifetime analysis showed 
incremental cost of € 2,792 and incremental QALY of 0.28. The ICER for ivabradine 
was calculated to be € 9,986 per QALY gained. The PSA showed that the likelihood 
